[CINCINNATI, OH, JUNE 16, 2015] – Schulman Associates IRB, Inc., the industry-leading central IRB in customer service and technology, announces the acquisition of Missouri-based Absolute Research. Additionally, Absolute Research founder Rebecca Ballard will be joining the Schulman team as Vice President of Compliance and Board Operations.
The transaction allows for significant investment to expand Absolute Research’s innovative technology offerings for the clinical research community, and Ms. Ballard’s substantial research ethics and legal expertise, as well as her leadership experience in the institutional research setting, bring valuable perspectives and knowledge to the organization.
“We are thrilled to join forces with Absolute Research and Rebecca Ballard,” said Michael Woods, President and CEO at Schulman. “Ms. Ballard’s talents and expertise and the tools she has developed through Absolute Research provide strategic advantages never seen before in the research community and will offer Schulman’s sponsor, CRO, site and institutional clients unparalleled efficiencies in clinical research conduct.”
Absolute Research’s technology offerings, including Animated Consent and Absolute Core, will be branded through Schulman’s joint venture Provision Research Compliance Services. Ms. Ballard will join Schulman’s staff in September 2015.
About Schulman Associates IRB, Inc.
Schulman Associates IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its joint venture partner Provision Research Compliance Services, offering comprehensive solutions to improve overall quality standards for clinical studies and data integrity, and to maximize the protection of human subjects. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.